(Q46474120)

22 December 2017

title

Priming and boosting determinants on the antibody response to an Epidermal Growth Factor-based cancer vaccine (English)

1 reference

22 December 2017

1 reference

Pedro C Rodriguez

1

1 reference

22 December 2017

Ileana Gonzalez

2

1 reference

22 December 2017

Adys Gonzalez

3

1 reference

22 December 2017

Janet Avellanet

4

1 reference

22 December 2017

Armando Lopez

5

1 reference

22 December 2017

Rolando Perez

6

1 reference

22 December 2017

Agustin Lage

7

1 reference

22 December 2017

Enrique Montero

8

1 reference

22 December 2017

language of work or name

English

0 references

publication date

18 July 2008

1 reference

22 December 2017

published in

Vaccine

1 reference

22 December 2017

volume

26

1 reference

22 December 2017

issue

36

1 reference

22 December 2017

page(s)

4647-4654

1 reference

22 December 2017

cites work

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

7 January 2021

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

Development trends for new cancer therapeutics and vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

Cancer vaccines: pessimism in check

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

Tumor-specific immunotherapy based on dominant models of natural tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

Cancer immunotherapy: moving beyond current vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

Inducing autoimmune disease to treat cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

The use of oil adjuvants in therapeutic vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

Therapeutic cancer vaccines: at midway between immunology and pharmacology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth f

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

Cancer vaccines for hormone/growth factor immune deprivation: a feasible approach for cancer treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: analysis of pooled data from three clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

T cell Ir phenotype modified by excising primary antigen deposit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

Regulation of the immune response by antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

Antigen localization and migration in immunity and tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

Multiple-site DNA vaccination enhances immune responses in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

Multisite intradermal antirabies vaccination. Immune responses in man and protection of rabbits against death from street virus by postexposure administration of human diploid-cell-strain rabies vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

Prospective immunogenicity study of multiple intradermal injections of rabies vaccine in an effort to obtain an early immune response without the use of immunoglobulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

Multi-site intradermal and multi-site subcutaneous rabies vaccination: improved economical regimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

Factors influencing the immune response to foreign antigen expressed in recombinant BCG vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

Dose and timing requirements for immunogenicity of viral poultry vaccine antigen: investigations of emulsion-based depot function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

Spatial distribution of tumor vaccine improves efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

T-cell-B-cell cooperation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

Autoimmunization to epidermal growth factor, a component of the immunological homunculus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

Receptors for epidermal growth factor and other polypeptide mitogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

Isolation and structure of urogastrone and its relationship to epidermal growth factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

Fetal effects of epidermal growth factor deficiency induced in rats by autoantibodies against epidermal growth factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

An immunologic approach to induction of epidermal growth factor deficiency: induction and characterization of autoantibodies to epidermal growth factor in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

The requirement of more than one antigenic determinant for immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

Generation and maintenance of immunological memory

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

Protective long-term antibody memory by antigen-driven and T help-dependent differentiation of long-lived memory B cells to short-lived plasma cells independent of secondary lymphoid organs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

Maintenance of serological memory

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

Cell mediated immune response elicited in mice after immunization with the P64k meningococcal protein: epitope mapping.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

B-cell epitope mapping of the Neisseria meningitidis P64k protein using overlapping peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

P64k meningococcal protein as immunological carrier for weak immunogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

Lifetime of plasma cells in the bone marrow.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

Humoral immunity due to long-lived plasma cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

Maintenance of serum antibody levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

B lymphocytes as autoantigen-presenting cells in the amplification of autoimmunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

Stimulation of a memory B cell response does not require primed helper T cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

Maintenance of serological memory by polyclonal activation of human memory B cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

A simplified 4-site economical intradermal post-exposure rabies vaccine regimen: a randomised controlled comparison with standard methods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

Biomarkers of immunosenescence within an evolutionary perspective: the challenge of heterogeneity and the role of antigenic load

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

Localization dose and time of antigens determine immune reactivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

Kinetics of TCR use in response to repeated epitope-specific immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

Phenotypic and functional maturation of tumor antigen-reactive CD8+ T lymphocytes in patients undergoing multiple course peptide vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

Booster vaccination in the elderly: their success depends on the vaccine type applied earlier in life as well as on pre-vaccination antibody titers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

Antigenicity: Some Molecular Aspects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

Immune responses to Ro60 and its peptides in mice. I. The nature of the immunogen and endogenous autoantigen determine the specificities of the induced autoantibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.07.003

10.1016/J.VACCINE.2008.07.003

7 January 2021

Identifiers

DOI

1 reference

22 December 2017

1 reference

22 December 2017